Division of Nephrology and Hypertension, Mayo Clinic, Guggenheim 542, 200 First St., SW, Rochester, MN 55905, USA.
Am J Physiol Regul Integr Comp Physiol. 2010 Nov;299(5):R1183-91. doi: 10.1152/ajpregu.00212.2010. Epub 2010 Aug 11.
ANG II causes renal injury through hemodynamic and other effects, and pressor doses of ANG II induce heme oxygenase-1 (HO-1) as a protective response. The present studies examined the hemodynamic effects of more clinically relevant, lower doses of ANG II and the role of HO activity in influencing these effects. Under euvolemic conditions, ANG II increased arterial pressure and renal vascular resistance. ANG II did not induce oxidative stress, inflammation/injury-related gene expression, or proteinuria and did not alter extrarenal vascular reactivity. At these doses, ANG II failed to increase HO-1 or HO-2 mRNA expression or HO activity. Inhibiting HO activity in ANG II-treated rats by tin mesoporphyrin further increased renal vascular resistances, decreased renal blood flow, and blunted the rise in arterial pressure without inducing oxidative stress or altering expression of selected vasoactive/injury/inflammation-related genes; tin mesoporphyrin did not alter vasorelaxation of mesenteric resistor vessels. We conclude that in this model renal vasoconstriction occurs without the recognized adverse effects of ANG II on glomerular filtration rate, renal blood flow, oxidative stress, vascular reactivity, proteinuria, and injury-related gene expression; renal HO activity is essential in preserving perfusion of the ANG II-exposed kidney. These findings represent an uncommon example wherein function of a stressed organ (by ANG II), but not that of the unstressed organ, requires intact renal HO activity, even when the imposed stress neither induces HO-1 nor HO activity. These findings may be germane to conditions attended by heightened ANG II levels, ineffective renal perfusion, and susceptibility to acute kidney injury.
血管紧张素 II 通过血液动力学和其他作用导致肾损伤,加压剂量的血管紧张素 II 诱导血红素加氧酶-1(HO-1)作为一种保护反应。本研究检查了更具临床相关性的较低剂量血管紧张素 II 的血液动力学效应,以及 HO 活性在影响这些效应中的作用。在血容量正常的情况下,血管紧张素 II 增加动脉血压和肾血管阻力。血管紧张素 II 不会引起氧化应激、炎症/损伤相关基因表达或蛋白尿,也不会改变肾外血管反应性。在这些剂量下,血管紧张素 II 未能增加 HO-1 或 HO-2 mRNA 表达或 HO 活性。在血管紧张素 II 处理的大鼠中,通过锡原卟啉抑制 HO 活性进一步增加肾血管阻力,减少肾血流量,并减弱动脉压升高,而不会引起氧化应激或改变选定的血管活性/损伤/炎症相关基因的表达;锡原卟啉不会改变肠系膜阻力血管的血管舒张。我们的结论是,在这种模型中,肾血管收缩发生而没有血管紧张素 II 对肾小球滤过率、肾血流量、氧化应激、血管反应性、蛋白尿和损伤相关基因表达的公认不良影响;肾 HO 活性对于维持暴露于血管紧张素 II 的肾脏的灌注是必需的。这些发现代表了一种罕见的情况,即在施加的应激既不诱导 HO-1 也不诱导 HO 活性的情况下,受应激器官(通过血管紧张素 II)的功能,但不是未受应激器官的功能,需要完整的肾 HO 活性。这些发现可能与伴有升高的血管紧张素 II 水平、无效的肾灌注和易发生急性肾损伤的情况有关。